Was Enobia’s Sale A High Water Mark For Rare Disease Deals?
This article was originally published in Start Up
Executive Summary
Alexion’s “hotly contested” purchase of Enobia last December didn’t get much attention, but it marked a watershed year for rare disease drug deals. Will high drug prices, skittish regulators and a gold-rush push by Big Pharma start to sour the sector?